Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation
Open Access
- 22 March 2014
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 132 (2), 211-219
- https://doi.org/10.1159/000357394
Abstract
Novel agents such as thalidomide, lenalidomide and bortezomib have dramatically changed the treatment paradigm of multiple myeloma (MM). However, it is not clear whether these agents improve the prognosis of elderly patients who have undergone autologous stem cell transplantation (auto-SCT). We retrospectively analyzed the outcome of 318 newly diagnosed patients aged 65-70 years who were treated between January 1, 2004, and December 31, 2009. As initial therapy, 192 patients were treated with conventional chemotherapy, 88 with novel agent-containing regimens, 21 with conventional chemotherapy plus auto-SCT and the remaining 17 with novel agents plus auto-SCT. The median progression-free survival was 19.1, 24.5, 26.8 and 35.2 months, respectively, and the 5-year overall survival (OS) was 40, 62, 63 and 87%, respectively. Initial therapy with novel agents (p < 0.001) or auto-SCT (p < 0.02) significantly improved OS compared with the group without these treatment modalities. Salvage therapy with novel agents also significantly improved survival after relapse compared with conventional chemotherapy alone (p < 0.04). In a multivariate analysis, the use of novel agents was an independent prognostic factor significantly associated with extended OS (p < 0.003). These results indicate that novel agents and auto-SCT had a major impact on OS in eligible patients in this subgroup of MM.Keywords
This publication has 14 references indexed in Scilit:
- Long-term prognostic significance of response in multiple myeloma after stem cell transplantationBlood, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsBlood, 2011
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysisAmerican Journal of Hematology, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myelomaBlood, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005